Work

Roxadustat for ESA ‐Hyporesponsive Renal Anemia in a 13‐Year‐Old on Hemodialysis: Case Report and Mini‐Review

Year: 2025

Type: article

Abstract: Anemia is the most common complication of end-stage renal disease (ESRD). While erythropoiesis-stimulating agents (ESA) have improved treatment outcomes, some patients exhibit intolerance or hyporesponsiveness. Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), improves erythropoiesis and iron metabolism, offering advantages in ESA-refractory cases. However, its use in pediatric populations remains limited. We present a case of a 13-year-old girl on maintenance hemodialysis who exhibited both hyporesponsiveness and intolerance to ESA. Initiation of oral Roxadustat resulted in a sustained improvement in hemoglobin levels, accompanied by notable enhancements in iron metabolism and clinical symptoms. So far, over 5 years of follow-up, no significant adverse events were observed. Oral Roxadustat appears to be an effective and safe treatment option for teenage hemodialysis patients who are resistant or intolerant to ESA.

Source: Clinical Case Reports

DOI: 10.1002/ccr3.70985

Authors: Meng Zhang, Yanchao Guo, Yan Zhu, Juan Yang

Institutions: Tongji Hospital, Huazhong University of Science and Technology

Language: English

Topic: Erythropoietin and Anemia Treatment

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,820